COMPLETE RESEARCH GUIDEPEPTIDE PEN
CJC-1295
GH Secretagogue Research Peptide
>99%5 mgFROM EUR 109
QUICK ANSWER
CJC-1295 (gh secretagogue research peptide) is a >99% purity research compound. A GHRH analogue (CJC-1295) investigated for growth hormone pathway modulation. Studies indicate CJC-1295 may stimulate pulsatile GH release via pituitary GHRH receptors. ORYN delivers CJC-1295 in a precision-dosed reusable pen starting from EUR 109. All products are for research purposes only.
Science & Research
FULL ENCYCLOPEDIA ENTRY →MOLECULAR PROFILE
FORMULA
C152H252N44O42
WEIGHT
3367.97 Da
CLASSIFICATION
Growth Hormone-Releasing Hormone (GHRH) Analogue
STUDIES CITED
4 key studies
Mechanism of Action
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) that binds to the GHRH receptor on somatotroph cells in the anterior pituitary gland. Upon receptor activation, it stimulates the synthesis and pulsatile release of growth hormone (GH) into the bloodstream.
READ FULL MECHANISM →Key Published Studies
2006
Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295
A single dose elevated GH levels 2-10 fold and IGF-1 levels 1.5-3 fold for up to 28 days in healthy adults.
2008
Effects of a growth hormone-releasing hormone analog on sleep in healthy men
Demonstrated increased slow-wave (deep) sleep duration and improved sleep quality in subjects receiving GHRH analogue treatment.
2009
Synergistic effects of GHRH and GHRP on pulsatile GH secretion
Showed combining GHRH analogues with ghrelin-pathway peptides produces synergistic rather than merely additive GH release.
2012
CJC-1295 effects on body composition and metabolic markers
Reported improvements in lean body mass, fat reduction, and metabolic markers in subjects with sustained GH elevation.
Research History
CJC-1295 was developed in the mid-2000s by ConjuChem Biotechnologies (now Conjuchem LLC) as a long-acting GHRH analogue designed to overcome the ultra-short half-life of endogenous GHRH. The original formulation with DAC (Drug Affinity Complex) showed dramatic increases in mean GH and IGF-1 levels in human trials.
FULL RESEARCH HISTORY →ORYN CJC-1295 Product
PEPTIDE PEN
CJC-1295 — GH Secretagogue Research Peptide
A GHRH analogue (CJC-1295) investigated for growth hormone pathway modulation. Studies indicate CJC-1295 may stimulate pulsatile GH release via pituitary GHRH receptors. Delivered in ORYN's reusable pen system with 5mg/3ml for 30 days of precision dosing.
PURITY
>99%
FILL VOLUME
3 mL
DOSAGE
5 mg
FORMULATION
Pharma Grade
DOSING PERIOD
30 Days
STERILIZATION
0.22um Filter + Gamma Ray
EUR 109VIEW PRODUCT DETAILS
Articles & Guides
ALL ARTICLES →GUIDES
Peptide Pen vs Vial: Which Is Better for Research?
A detailed comparison of peptide pen systems versus traditional vials for research applications. Why pre-mixed pens are becoming the new standard.
6 min read
GUIDES
How to Use a Peptide Pen: Step-by-Step Guide
Step-by-step instructions for using ORYN peptide pen systems. From unboxing to administration, everything you need to know.
5 min read
GUIDES
Peptide Storage Guide: Temperature, Shelf Life & Best Practices
Proper peptide storage is critical for maintaining potency and research reliability. Learn the best practices for temperature control, shelf life management, and safe transport.
7 min read
PEPTIDE RESEARCH
Ipamorelin vs CJC-1295: Growth Hormone Peptide Comparison
A comprehensive comparison of ipamorelin and CJC-1295 — two growth hormone peptides with distinct mechanisms and powerful synergy when used together.
9 min read
EDUCATION
Peptide Pens for Beginners: Everything You Need to Know (UK Guide)
Starting peptide research in the UK? This beginner's guide covers everything from pen basics to storage, safety, and selecting your first research compound.
10 min read
RESEARCH GUIDES
Peptides for Athletes & Sports Recovery UK: Research Guide 2026
An in-depth look at peptide research relevant to athletic performance, sports recovery, and exercise science in the UK.
11 min read
Head-to-Head Comparisons
ALL COMPARISONS →COMPARISON
CJC-1295 vs Ipamorelin: Growth Hormone Peptides Compared
CJC-1295VSIpamorelin
CJC-1295 and Ipamorelin work through different GH pathways and are most commonly studied together for synergistic effects. CJC-1295 extends GH release duration, while Ipamorelin triggers clean GH pulses. The combination is one of the most popular GH research stacks.
COMPARISON
TB-500 vs CJC-1295: Wound Healing vs Growth Hormone Releasing
TB-500VSCJC-1295
TB-500 excels at direct tissue repair — wound healing, angiogenesis, and reducing inflammation at injury sites. CJC-1295 stimulates sustained growth hormone release for body composition, recovery, and anti-ageing research. They target different biological systems and are frequently combined in advanced protocols.
COMPARISON
CJC-1295 vs Semaglutide: Growth Hormone vs Weight Loss Peptide
CJC-1295VSTirzepatide
CJC-1295 and Semaglutide (compared here alongside Tirzepatide) serve entirely different purposes. CJC-1295 is a GHRH analogue for sustained growth hormone research — body composition, recovery, sleep, and anti-ageing. Semaglutide and Tirzepatide are incretin-based compounds for metabolic and weight management research. ORYN offers CJC-1295 for GH protocols and Tirzepatide (which surpasses Semaglutide in clinical data) for metabolic protocols.
COMPARISON
BPC-157 vs CJC-1295: Recovery Peptide vs Growth Hormone Peptide
BPC-157VSCJC-1295
BPC-157 is the stronger choice for direct tissue recovery — gut healing, tendon repair, and neuroprotection through growth factor modulation. CJC-1295 is the better option for growth hormone optimisation — body composition, sleep, and systemic recovery via sustained GH release. They work through entirely different pathways and are commonly stacked for comprehensive recovery protocols.
COMPARISON
Tirzepatide vs CJC-1295 for Weight Management: Which Approach Works?
TirzepatideVSCJC-1295
For direct weight management research, Tirzepatide is overwhelmingly superior — clinical trials show 15-21% body weight reduction through dual GIP/GLP-1 receptor action. CJC-1295 supports body composition indirectly through sustained GH release, improving lean mass and fat metabolism. They represent fundamentally different approaches: Tirzepatide reduces weight through appetite and metabolic regulation, whilst CJC-1295 improves body composition through anabolic GH pathways.
COMPARISON
Ipamorelin vs CJC-1295: Two GH Peptides, Different Mechanisms
IpamorelinVSCJC-1295
Ipamorelin and CJC-1295 both stimulate growth hormone release but through entirely different receptor pathways. Ipamorelin triggers clean, selective GH pulses via the ghrelin receptor. CJC-1295 extends GH release duration via the GHRH pathway. Individually, each is effective. Together, they produce synergistic GH elevation that exceeds either compound alone — which is why the CJC-1295 + Ipamorelin stack is the most popular GH research protocol worldwide.
COMPARISON
Ipamorelin vs CJC-1295: Solo Use vs Stacking for GH Research
IpamorelinVSCJC-1295
Ipamorelin solo is the cleanest, safest GH secretagogue with minimal hormonal side effects -- ideal for beginners or GH-isolated research. CJC-1295 solo provides sustained GH elevation for more aggressive protocols. However, the combination of both is the gold standard, producing synergistic GH release through dual-pathway activation that exceeds either peptide alone.
COMPARISON
CJC-1295 vs Ipamorelin vs Both: Complete GH Peptide Decision Guide
CJC-1295VSIpamorelin
Each option serves a distinct purpose. CJC-1295 solo provides sustained GH elevation for body composition and IGF-1-focused research. Ipamorelin solo provides clean, pulsatile GH release with the fewest side effects -- ideal for GH-isolated studies. The combination is the gold standard, producing synergistic GH output through dual-pathway activation. For most researchers, the stack is worth the additional investment.
Research Protocols
ALL PROTOCOLS →PERFORMANCE
8-12 weeksCJC-1295 + Ipamorelin GH Protocol
Precision Growth Hormone Optimization Stack
CJC-1295Ipamorelin
PERFORMANCE
12-16 weeksCJC-1295 + Ipamorelin + BPC-157 Athletic Protocol
Performance, Recovery & Growth Optimization Stack
CJC-1295IpamorelinBPC-157
METABOLIC
16-20 weeksTirzepatide + CJC-1295 Body Recomp Protocol
Simultaneous Fat Loss & Lean Tissue Preservation
TirzepatideCJC-1295
Frequently Asked Questions
FULL FAQ →What is CJC-1295 and how does it work?
+
CJC-1295 is a synthetic analogue of Growth Hormone-Releasing Hormone (GHRH) that stimulates the pituitary gland to produce and release growth hormone. It has been modified with amino acid substitutions to resist enzymatic degradation, giving it a significantly longer half-life than natural GHRH.
What is the difference between CJC-1295 with and without DAC?
+
CJC-1295 with DAC (Drug Affinity Complex) binds to circulating albumin, extending its half-life to several days and providing sustained GH elevation. CJC-1295 without DAC (Mod GRF 1-29) has a shorter duration of action, producing more natural pulsatile GH release patterns. Both versions stimulate the same GHRH receptor.
What research supports CJC-1295?
+
Clinical trials have shown a single injection can elevate GH levels 2-10 fold and IGF-1 levels up to 3 fold for up to 28 days. Research also demonstrates improved sleep quality, enhanced body composition, and synergistic effects when combined with ghrelin-pathway peptides like Ipamorelin.
How does ORYN deliver CJC-1295?
+
ORYN CJC-1295 is formulated at 5mg in a 3mL precision pen system with >99% purity. The pre-mixed pen ensures accurate dosing over 30 days, maintaining peptide stability and eliminating the reconstitution process required with traditional lyophilised vials.
What is CJC-1295?
+
CJC-1295 is a synthetic 30-amino acid peptide analogue of growth hormone-releasing hormone (GHRH). It is designed to provide sustained stimulation of GH release from the pituitary gland. ORYN CJC-1295 is formulated at >99% purity with a 5 mg dose in a precision pen system for consistent research-grade administration.
How does CJC-1295 work?
+
CJC-1295 binds to the GHRH receptor on pituitary somatotroph cells, stimulating the release of growth hormone in a pulsatile manner. Its modified structure resists enzymatic degradation, resulting in a longer half-life compared to native GHRH. This sustained activity allows for prolonged GH elevation in research subjects. These observations come from preclinical and clinical research studies.
What is CJC-1295 used for in research?
+
CJC-1295 is studied in research contexts related to growth hormone secretion, body composition, sleep quality, metabolic function, bone density, and age-related GH decline. It is one of the primary peptides used in growth hormone axis research.
How is ORYN CJC-1295 administered?
+
ORYN CJC-1295 is delivered via a pre-mixed pen containing 5 mg in 3 mL. The pen is designed for subcutaneous injection, typically administered in the evening to align with natural GH release patterns. No reconstitution is required.
Explore More ORYN Products
RESEARCH PURPOSES ONLY. All content on this page is intended for informational and educational purposes for qualified researchers. ORYN products are not approved as medicines and are not intended for human therapeutic use. Do not use ORYN products for self-administration. Consult relevant regulations in your jurisdiction.